Viking Therapeutics Stock Rises on Positive Weight Loss Drug Results

2026-09-22 companies

San Diego, Tuesday, 22 September 2026.
Viking Therapeutics shares climbed after trial data revealed its obesity drug maintained up to 97% of weight loss with monthly or biweekly dosing, offering flexible treatment options.

Market Momentum and Stock Performance

Shares of clinical-stage biopharmaceutical firm Viking Therapeutics Inc. (NASDAQ: VKTX) recorded five consecutive days of market gains in September 2026, driven by investor optimism surrounding clinical trials for its novel metabolic and obesity candidates [1]. On 2026-09-21, Viking Therapeutics stock closed at $30.11, representing a 3.863 gain from the previous close of $28.99 [3]. Trading volume increased by 2 million shares to a total of 5 million shares traded on that day, amounting to approximately $152.29 million [3]. Intra-day volatility reached 8.06%, with the stock currently facing resistance levels at $30.21 and $32.94 [3]. Despite the recent surge, the stock had been a sell candidate since 2026-09-03 with a total loss of -11.39% prior to this rally [3].

Clinical Trial Results and Drug Efficacy

The market momentum reflects high expectations for the company’s positioning within the rapidly expanding weight-loss drug sector as analysts monitor forthcoming maintenance data [1]. Viking Therapeutics reported positive top-line results on 2026-09-21 from a randomized, double-blind, placebo-controlled maintenance study of its dual GLP-1/GIP agonist VK2735 [7]. The study demonstrated 22% placebo-adjusted weight loss at Week 33 following weekly 17.5 mg dosing, with no plateau observed through 33 weeks [6]. In the 12-week maintenance phase, subjects transitioning to every-other-week dosing maintained up to 97% of prior weight loss, while those on monthly dosing maintained up to 90% [7]. This compares to 61% maintenance for the placebo group, indicating a favorable tolerability profile with gastrointestinal adverse event rates similar to placebo [7].

Financial Position and Operational Costs

Despite reporting zero revenue and a widened net loss in its recent quarterly SEC filing, the company maintains significant liquidity to support operations [1]. For the six months ended 2026-06-30, Viking Therapeutics reported a net loss of $286.3 million, which is a 157.464 increase from the $111.2 million loss reported year-over-year [2]. Research and development expenses were $265.9 million for the same period, up from $101.5 million year-over-year, supporting Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials [2]. As of 2026-06-30, liquidity included $125.8 million in cash and equivalents and $375.9 million in short-term investments [2]. Operating cash outflow was $239.1 million for the first half of 2026 [2].

Analyst Outlook and Future Catalysts

Analysts identify upcoming 3Q26 readouts for both VK3019 and VK2735 as key near-term catalysts for the company [4]. Oppenheimer reiterated an Outperform rating on Viking Therapeutics with a price target of $100, seeing VK2735 maintenance data potentially supporting flexible dosing and market-share gains [5]. Viking Therapeutics intends to advance the oral tablet formulation of VK2735 into late-stage development by the end of 2026 [4]. The next earnings date for Viking Therapeutics is scheduled for 2026-10-28 [3]. Retail sentiment for VKTX has shifted to extremely bullish levels, with message volume reaching high levels on platforms like StockTwits [4].

Sources

Biotechnology Pharmaceuticals